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Abstract
Historically, few data exist to guide dosing in children and pregnant women. Multiple barriers to 
inclusion of these vulnerable populations in clinical trials have led to this paucity of data. 
However, federal legislation targeted at pediatric therapeutics, innovative clinical trial design, use 
of quantitative clinical pharmacology methods, and pediatric thought leadership and collaboration 
have successfully overcome many existing barriers. This success has resulted in improved 
knowledge on pharmacokinetics, safety, and efficacy of therapeutics in children. To date, research 
in pregnant women has not been characterized by similar success. Wide gaps in knowledge remain 
despite the common use of therapeutics in pregnancy. Given the similar barriers to drug research 
and development in pediatric and pregnant populations, the route toward success in children may 
serve as a model for the advancement of drug development and appropriate drug administration in 
pregnant women.
Introduction
Physiologic changes during pregnancy alter drug disposition (pharmacokinetics [PK]) and 
the body’s response (pharmacodynamics [PD]) to drugs. As a result, optimal drug dosing in 
pregnant women that maximizes efficacy and minimizes toxicity to both mother and fetus, is 
likely different from dosing in non-pregnant women. However, few data are available to 
guide drug dosing in pregnant women. The lack of data has led to a paucity of drugs labeled 
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for use in pregnant women, and the widespread prescription of drugs for off-label use in this 
population. In a recent study of nearly 18,000 prescriptions for 235 different drugs to 
hospitalized, pregnant women, nearly 75% (13,249) of prescriptions for 84% (198) of drugs 
were not labeled for use in pregnancy.1 Given the substantial burden of off-label use in 
pregnant women, clinical data are urgently needed to guide drug administration in this 
vulnerable population.
Although multiple barriers exist to gathering this clinical data through rigorous scientific 
study, pediatric research has proved successful in overcoming similar barriers in children. 
Pediatric research may therefore serve as a model for the advancement in knowledge of 
pharmacotherapy for pregnant women.
Historical barriers to improving pharmacotherapy in pregnant women
Most drugs are not studied in pregnant women prior to FDA approval. Historically, research 
ethics regarding risks to the fetus led to the exclusion of pregnant women from early-phase 
clinical trials.2 Further, drug sponsors have been hesitant to perform clinical trials that enroll 
pregnant women given the potential risks of litigation associated with drug-induced injury to 
the mother and fetus.3 Therefore, animal reproductive studies largely provide the basis for 
pregnancy risk categorization. Post-marketing surveillance data is subsequently used to 
determine fetal risk after drug exposure. This approach has not only slowed progress in drug 
development for pregnant women, but also permits undue fetal risk. The case of thalidomide 
serves as a prime example. In the late 1950s, thalidomide was an over-the-counter drug used 
off-label in many pregnant women for treatment of morning sickness. Phocomelia was 
observed in human infants, and animal testing subsequently occurred to determine the 
association between thalidomide and phocomelia. However, depending on the species of the 
experimental animal, this testing did not reliably predict the teratogenic nature of 
thalidomide.4 Animal studies have similarly been of limited value for other teratogens, 
underscoring the importance of drug evaluation in pregnant women.4
Legislative enactments have begun to pave the way for improvements in the study and use 
of drugs in pregnant women. The National Institute of Health Revitalization Act of 1993 
acknowledged need for inclusion of pregnant women in early-phase clinical trials.5 In June 
2015, The Pregnancy and Lactation Labeling Rule (PLLR) will eliminate use of pregnancy 
letter categories (A, B, C, D, and X) and will require updated product labels as information 
is available.6 Product labels will include information on infertility, contraception 
recommendations, and pregnancy testing as available. This information will assist healthcare 
providers and patients in making decisions based on the known risks and benefits of specific 
drug use in pregnancy.
Inclusion of pregnant women in clinical trials
Although there is growing awareness of the need to study drug use in pregnant women, 
practical challenges in the conduct of these studies remain. These challenges affect the drugs 
and drug doses chosen for study in clinical trials and the conduct of the trials themselves. 
Among these challenges are: 1) the physiology of pregnancy and changes in this physiology 
over time and 2) barriers to patient enrollment and follow-up.
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Changes in a woman’s physiology during pregnancy may alter drug absorption, distribution, 
metabolism, and elimination. Specifically, decreased intestinal motility and increased gastric 
pH could alter drug absorption, although existing studies do not substantiate a clinical 
impact of these changes on drug bioavailability.7,8 Second, the volume of distribution 
increases in pregnancy due to increases in plasma volume, total body water and maternal fat, 
in addition to decreased albumin concentrations. This increase in volume of distribution can 
lead to decreased initial plasma concentrations, requiring an increase in the loading dose.9 
Decreased albumin concentrations may also lead to toxicity for drugs that are dosed based 
on total plasma concentration (e.g., phenytoin).10 Third, drug metabolism may be increased 
or decreased dependent on the involved phase I or II isoenzyme. For example, multiple 
cytochrome P450 enzymes (e.g., CYP3A4, CYP2D6, and CYP2C9) and uridine diphosphate 
glucuronosyltranserase enzymes (UGT1A4 and UGT2B7) have increased activity during 
pregnancy, while others (CYP1A2 and CYP2C19) have decreased activity during this 
physiologic state.11 Increased metabolic activity may result in the need to increase drug 
dosing, and decreased activity may require decreased dosing. Finally, studies have 
determined variable effects of pregnancy on drug elimination. This variability is largely 
dependent on regional blood flow to the liver and kidneys, drug characteristics (i.e., high or 
low extraction), and the presence and activity of protein transporters. The interaction of 
these factors is incompletely understood; however, drugs that are renally excreted, 
unchanged, appear to have increased elimination during pregnancy and require increased 
dose to maintain plasma concentrations.11
The pregnant state not only affects drug disposition and pharmacologic activity, but 
developmental changes throughout pregnancy also result in alterations of drug distribution, 
metabolism, and elimination over time. For example, albumin concentrations decline 
throughout pregnancy, resulting in concentrations 70-80% of normal values at the time of 
delivery.12 CYP1A2 activity, important in the metabolism of caffeine, initially decreases in 
the first trimester and remains low through the third trimester compared to postpartum 
values.13,14 Investigators have found an increase in effective renal plasma blood flow up to 
80% by the second trimester 15 and a decrease in glomerular filtration during the last 3 
weeks of pregnancy.16 These changes over time present additional challenges in drug dosing 
and overall design of clinical trials. Chronic diseases and pregnancy-induced states (e.g., 
preeclampsia) likely further complicate the pharmacokinetics of drug therapy in pregnant 
women.17 Timing of dosing and sample collection must take these changes into account. 
Study of multiple pregnancy time periods and disease states is potentially necessary to 
capture these changes and adequately describe the PK/PD of a specific drug in pregnancy.
Unfortunately, this need to study multiple pregnancy time periods and disease states may 
also increase the required sample size. Even in the current era in which legislation is 
supportive of enrollment of pregnant women in clinical drug trials and drug sponsors are 
less reluctant to initiate studies in this population, consent rates may be low given potential 
risk to the fetus.18 Further, the classification of pregnant women as vulnerable research 
subjects demands that multiple conditions are met before research can proceed. Among 
these is the requirement for research to provide direct benefit or minimal risks, and that such 
benefit or risk is potentially interpretable by local institutional review boards (IRB).2
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Overcoming barriers in pediatric research
Like pregnant women, children are also classified as vulnerable research subjects. Federal 
regulations that require direct benefit to the subject usually allow enrollment only of 
children who are ill. This mandate substantially decreases the number of children eligible for 
inclusion in clinical trials. Low parenteral consent rates further impede enrollment in clinical 
trials.19
Increased understanding of developmental physiology has been central to our understanding 
of pharmacotherapy, but it presents an additional barrier to adequate enrollment of children 
in clinical trials. Developmental physiology suggests that age, patient size, and maturation of 
hepatic isoenzymes and renal function over time, greatly impact drug PK/PD. For example, 
investigators have described a non-linear relationship between increased glomerular 
filtration rate and postmenstrual age; half-maximal adult values are not reached until 
approximately 50 weeks postmenstrual age.20 Similarly, maturation of hepatic isoenzymes 
increases at a variable rate; CYP1A2 reaches only 40% of adult activity between the ages of 
1 and 10, whereas CYP3A4 reaches 100% of adult activity during this time frame.21 This 
maturation of renal and hepatic function suggest that the PK/PD of a drug in a neonate is 
likely different from that in infants, children, adolescents, or adults. These differences 
suggest the need to study PK/PD across the age continuum and in variable disease states, 
thereby increasing the number of patients needed to sufficiently improve understanding of 
drug PK/PD in children.
Over the last 15 years, investigators have made substantial strides in overcoming barriers to 
increase knowledge of PK, safety, and efficacy of drugs in children. In the United States, the 
Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act 
(PREA) have provided the regulatory framework for evaluation of drug use in children. 
Further, incentives to drug sponsors for development of on and off-patent therapeutics and 
requirements for conduct of pediatric studies for new drug products, have all provided 
impetus for study of pediatric therapeutics. With legislative backing, pediatric researchers 
have developed innovative clinical trial design, increased clinical pharmacology expertise 
and training, and initiated extensive collaborations that have led to success in efforts to 
increase knowledge toward more optimal drug dosing in children.
Innovative clinical trial design
Recent design of clinical trials has specifically targeted barriers to enrollment, to make 
possible the large sample sizes needed to describe the PK of drugs across the age continuum 
in pediatric patients. Specifically, protocols that include broad inclusion criteria and the 
study of multiple drugs in a single population have improved patient eligibility for drug 
trials. The use of a single protocol across multiple sites and the implementation of networks 
of clinical trial sites has helped to overcome low consent rates that may limit enrollment at 
one site.22 The Eunice Kennedy Shriver National Institute Child Health and Human 
Development (NICHD) has sponsored two such initiatives, including: the Pediatric 
Pharmacology Research Unit (PPRU; 2000-2010); and the Pediatric Trials Network (PTN; 
2010-present). Similar networks exist in Canada (the Maternal Infant Child, Youth Research 
Network, MICYRN; 2006-present), and the United Kingdom (the National Institute for 
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Health Research, NIHR, and the Medicines for Children Research Network MCRN; 2006-
present).
Pediatric investigators have also carefully chosen drugs for study and methods for sample 
collection. Researchers have capitalized on drugs administered per standard of care, 
opportunistic drug sampling (samples taken at the time of routine blood draws), and 
scavenged PK samples (leftover samples from routine care of patients).22 Further, pediatric 
trials have begun to incorporate sampling of other sources, including urine, cerebrospinal 
fluid, and other body fluids that may be collected per standard of care. These minimal risk 
methods not only help increase the quantity and breadth of available drug information, but 
may also help increase the likelihood of local IRB protocol approval and parental consent.22
Quantitative clinical pharmacology and innovative bioanalytical techniques
Opportunistic study design may increase the quantity and breadth of available PK/PD 
information in pediatric patients, improve efficiency in data collection, and ensure that 
research efforts focus on drugs relevant to clinical practice. However, the acquisition of 
quality data that 1) permits description of PK/PD across both distribution and elimination 
phases, 2) permits description across the pediatric age continuum, and 3) considers efficient 
use of resources, has also required the application of quantitative methods in clinical 
pharmacology and innovative bioanalytical techniques.
Population and physiologically-based PK/PD modeling and simulation techniques have had 
multiple uses in pediatric clinical trial design and description of drug disposition across the 
age continuum. Modeling and simulation often use adult data and apply principles of 
developmental physiology to predict optimal dosing for study and ideal sampling times for 
capture of distribution and elimination phases. Physiologically-based models incorporate 
drug properties, physiology, and efficacy targets that allow prediction of drug doses for 
study that may result in efficacy or toxicity. Moreover, population PK/PD modeling allows 
collection of meaningful data despite the sparse sampling that is often necessary in 
opportunistic drug trials. Further, modeling permits the combination of data from multiple 
pediatric age groups in order to describe the changes that occur with maturation. Population 
and physiologically-based PK/PD modeling and simulation have been central to adequate 
preparation for clinical trials in children and may reduce the sample size needed for full 
characterization of PK/PD in some drugs. The results of such preparation are reduced 
clinical trial expense, increased likelihood of achieving desired therapeutic exposures, and 
maximized information gained from the trials.
Improvements in bioanalysis of pediatric samples may have a similar effect to PK/PD 
modeling in decreasing costs and improving efficiency of translating trial data into clinically 
useful information. Specifically, pediatric trials have expanded sample collection to dried 
blood, plasma, and urine matrices. The comparability of drug concentrations from dried to 
liquid matrices must be assessed for every drug; however, if comparable, analysis of dried 
matrices may have advantages over the liquid forms. Among these advantages are: smaller 
sample volumes, greater flexibility in sample collection, minimal personnel training, and the 
ability to store samples at room temperature. These advantages likely lead to decreased trial 
costs. Similarly, improved bioanalytical techniques have led to improved sensitivity and 
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selectivity in ascertainment of drug concentrations. Improved sensitivity and selectivity have 
in turn led to the ability to characterize multiple different drugs from a single sample 
through the use of multiplex assays. Characterization of multiple drugs in this manner 
improves efficiency of drug trials and decreases costs.
Thought leadership in pediatric clinical pharmacology
The intricacies of current pediatric drug trials and the successes observed in trial efficiency 
would not be possible without the formation of multidisciplinary research teams focused on 
pediatric drug development. Existing pediatric collaborative networks combine the expertise 
of researchers in pediatrics, quantitative clinical pharmacology, clinical trial design and 
execution, and regulatory sciences. These networks have also provided the framework for 
training the next generation of pediatric scientists with expertise in each of these areas.
Application of pediatric research methods to maternal fetal medicine: 
capitalizing on current knowledge and infrastructure
Application of existing pediatric research methods to narrow the knowledge gap for 
therapeutics used in pregnant women is certainly possible. Adaptation of minimal risk 
techniques through opportunistic trial designs may decrease the barriers to enrollment in 
clinical trials that stem from fear of risk to the fetus. The use of collaborative networks, 
including the NICHD-sponsored, 4-site Obstetric-Fetal Pharmacology Research Units 
(OPRU) Network (2004-present) has already proven successful in the determination of 
differences in drug clearance between pregnant and non-pregnant women for drugs such as 
indomethacin and oseltamivir.23,24 Expansion of this network and creation of others based 
on existing infrastructure at large academic centers can improve expertise, encourage 
multidisciplinary involvement in research teams, and increase access to pregnant patients in 
efforts to improve clinical research in pregnancy. Furthermore, implementation of multi-site 
protocols with broad inclusion criteria aimed at the study of multiple drugs, will improve 
efficiency in gathering data for clinical use in pregnancy.
Obstetric research can also adopt PK/PD modeling and simulation to plan for studies in 
pregnant women and maximize the use of data collected from clinical trials. Population PK 
models have already been developed in pregnant women to estimate PK parameters and 
identify inter- and intra-individual variability that has previously challenged the study of 
PK/PD during physiologic changes of pregnancy. Use of these parameters in concert with 
covariates such as gestational age, has allowed optimal dose selection for study in pregnant 
women and may reduce study sample size. Inclusion of drug concentrations from cord blood 
or amniotic fluid in these models also allows prediction of placental drug transfer.25 
Application of physiologically-based PK/PD modeling and simulation techniques in 
pregnancy using in vitro and in vivo data, including placental-fetal information, may further 
optimize dose predictions for maximal efficacy and minimal toxicity to mother and fetus. A 
few exemplary studies exist in pregnant women, including one that used the physiologically-
based PK approach to predict gestational age-dependent changes in drug exposure for 
methadone and glyburide, and another that used this approach to predict changes in 
exposure to caffeine, metoprolol, and midazolam.26,27
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Finally, pediatric legislation, including BPCA and PREA, has proven effective in increasing 
pediatric pharmacotherapy research. Similarly, legislation that supports obstetric research 
would help provide incentives and funding to increase the span and number of drug trials in 
pregnant women. Recently, the Society for Maternal Fetal Medicine, American Congress of 
Obstetrics and Gynecologists, March of Dimes, and American Academy of Pediatrics have 
launched the Coalition to Advance Maternal Therapeutics. This coalition will advocate for 
research and changes in health policy to increase knowledge on therapeutics in pregnancy.28
The existence of drug PK/PD models in pregnancy, a small collaborative research network 
specific to the study of obstetric patients, existing academic infrastructure, and increasing 
political influence, demonstrate the potential for safe and efficient improvement of drug 
development in pregnant women. The success of the pediatric experience despite similar 
classification of children and pregnant women as vulnerable populations, provides a worthy 
model for how leaders in obstetric research might improve and expand current efforts. As 
demonstrated in the pediatric experience, training the next generation of multidisciplinary 
experts in obstetric pharmacotherapy research, is essential in the move forward.
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